In an IBD mouse model, such as DSS- or 2,4,6-trinitrobenzenesulfonic acid (TNBS)-treated mice, the inhibition of the TGF-β1/Smad pathway reduced intestinal fibrosis46,47. Here, TGFB1 is linked to inflammatory bowel disease.